Skip to content
The Policy VaultThe Policy Vault

Zelboraf (vemurafenib) — Medica

Histiocytic neoplasm (Langerhans cell histiocytosis)

Initial criteria

  • age ≥ 18 years
  • Langerhans cell histiocytosis
  • BRAF V600 mutation-positive disease

Approval duration

1 year